EGFR and non-small cell lung carcinoma: Direct monitoring of T790M mutation in both CTCs and ctDNAs were employed to potentially guide treatment selection on EGFR-mutant non-small cell lung cancer (NSCLC) patients (Sundaresan et al., 2016).